Written by The global asthma treatment market is witnessing steady expansion, supported by the rising prevalence of asthma, growing awareness about disease management, increasing adoption of combination therapies, and continued innovation in inhalation technologies. Valued at approximately US$ 24.0 Bn in 2021, the global industry is projected to expand at a CAGR of 3.7% from 2022 to 2031, reaching more than US$ 34.5 Bn by the end of 2031. Increasing healthcare expenditure and greater emphasis on early diagnosis and long-term disease management are further expected to support market development.
👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=73640
Market Overview
Asthma is a chronic respiratory condition characterized by narrowing and swelling of the airways and increased mucus production, which can result in coughing, wheezing, and shortness of breath. While symptoms vary among patients, severe asthma attacks can disrupt daily activities and become life-threatening. Rising exposure to air pollution, passive smoking, allergens, and occupational irritants is contributing to the growing disease burden among adults and children.
According to the World Health Organization, asthma affected approximately 262 million people in 2019, while around 455,000 deaths were attributed to the disease. The growing number of patients is consequently generating sustained demand for effective asthma medications and delivery systems.
Market Size and Growth
Increasing awareness about asthma treatment is a key factor supporting market growth. Initiatives such as the CDC’s National Asthma Control Program, World Asthma Day, and asthma awareness campaigns encourage early diagnosis, appropriate treatment, and improved disease management. Asthma camps and awareness programs conducted by organizations such as the Asthma Society of India are also expected to contribute to market expansion.
Product innovation represents another significant growth opportunity. Pharmaceutical companies are increasingly investing in smart and digital inhalers, combination therapies, and convenient drug-delivery technologies. Collaborations are also shaping the competitive environment, including AstraZeneca’s partnership with Avillion to develop PT027, an asthma rescue inhaler.
Market Segmentation
By treatment, the market is segmented into long-term asthma control medications and quick-relief (rescue) medications. Long-term asthma control medications accounted for the dominant share in 2021, with inhaled corticosteroids remaining among the most effective options for sustained disease control.
Based on route of administration, the market is divided into inhaled, oral, intravenous, and subcutaneous therapies. The inhaled segment held a leading share in 2021 because inhaled medicines deliver treatment directly to the lungs and are widely preferred by patients and healthcare professionals.
By distribution channel, the market comprises hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies represented the largest segment in 2021, supported by increasing dispensing of asthma therapeutics and expansion of pharmacy networks in developing economies.
Regional Analysis
North America accounted for a major share of the global market in 2021, supported by regulatory approvals, extensive drug pipelines, advanced healthcare infrastructure, and greater emphasis on reducing undiagnosed asthma cases. Meanwhile, Asia Pacific is expected to register a higher CAGR during the forecast period. Increasing asthma prevalence, smoking, environmental pollution, and improving awareness of respiratory disease management in countries such as China and India are creating substantial growth opportunities.
Competitive Landscape
The global asthma treatment market remains relatively consolidated, with major pharmaceutical companies focusing on portfolio expansion, strategic collaborations, product innovation, and mergers and acquisitions. Prominent participants include AstraZeneca plc., Boehringer Ingelheim, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Merck & Co., Inc., Novartis International AG, Sanofi, Teva Pharmaceutical Industries, Mylan N.V., and Sunovion Pharmaceuticals, Inc.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:Â
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453